Latest Entitlement Offer News

Cyprium Metals has made substantial progress on its Nifty Copper Complex restart, targeting copper cathode production by September 2026 while securing A$41 million to fuel exploration and growth.

Alexium International Group has boosted sales to $1.03 million following its Microtek Laboratories acquisition, shifting focus to manufacturing-led growth and expanding its flame-retardant and thermal regulation product lines.

Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.

Reach Resources has boosted its Blue Heaven gold resource by roughly 30% to 80,000 ounces, supported by strong metallurgical results and a newly granted mining lease, while progressing a $3.15 million rights issue to fund further exploration and development.

Tamboran Resources has closed its retail entitlement offer, adding A$24.8 million to a total equity raise of A$282.6 million to fund expanded drilling and development in the Beetaloo Basin.

Verity Resources has completed an 11,000m drilling campaign at its Monument Gold Project, confirming and extending a 154,000oz inferred gold resource with high-grade, consistent intercepts and strong metallurgical recoveries.

Neometals Ltd has launched a 1-for-6 entitlement offer at A$0.04 per share alongside a two-tranche placement, targeting a combined A$13 million to advance gold and critical minerals projects.

HyTerra Ltd is progressing its flagship Nemaha hydrogen project with a key production test planned for Q2 2026, while expanding its global footprint through strategic partnerships and a $7 million capital raise.

Syrah Resources delivered a record 24kt graphite production at Balama and secured US$72 million in equity to support medium-term ramp-up and Vidalia commercialisation, navigating a complex US trade environment.

Horizon Gold has confirmed new high-grade gold shoots at its Kingfisher prospect, underpinning resource growth potential, while progressing a major $30 million capital raise and leadership transition.

PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.

Regener8 Resources has secured a binding agreement to acquire the Srebrenica North Project in Bosnia and Herzegovina, complemented by a successful $800,000 placement and a $2.87 million entitlement offer to fund exploration and due diligence.